Skip to main content

STUDY PROTOCOL article

Front. Med.
Sec. Obstetrics and Gynecology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1539880

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis

Provisionally accepted
Xiaolian Peng Xiaolian Peng 1*Jie Liu Jie Liu 2
  • 1 Xiegang Branch, Dongguan Municipal People's Hospital, Guang Dong Province, China, Dongguan, China
  • 2 Department of Vascular and Endovascular Surgery. Chinese PLA General Hospital, Beijing, China, Beijing, China

The final, formatted version of the article will be published soon.

    Introduction: Clinical trials have shown that PARP inhibitors are effective in treating patients with platinum-sensitive ovarian cancer. They have been indicated to improve progression-free survival or overall survival in patients with patients with platinum-sensitive ovarian cancer. However, there is insufficient comprehensive evidence regarding the comparison of different agents. To evaluate and compare the efficacy and side effects of various PARP inhibitors. Methods: We plan to conduct a network meta-analysis that includes randomized, double-blind, controlled phase III trials of Niraparib, Rucaparib, Olaparib, or Veliparib in patients withPlatinum-sensitive ovarian cancer. The primary outcomes will be progression-free survival or overall survival. The secondary outcome will be grade ≥3 of treatment-emergent adverse events. Published and unpublished studies will be retrieved through PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform from 1990 to 2023. We will use STATA V.14.0 to perform all analyses, and the RevMan software to report the risk of bias in the included studies. We will determine the quality of evidence using the GRADEpro GDT software online version. This is a protocol description only. Results and conclusions are subject to completion. This study will be based on published studies, since no primary data collection will be carried out, no formal ethical assessment is required. The network graph and meta-analysis will be used to compare all PARP inhibitors. Their ranking will employ a rankogram, surface under the cumulative ranking curves, and mean ranks. Discussion: Our study will answer the most important question in platinum-sensitive ovarian cancer: which PARPi should be preferred regarding efficacy and side effects? Trials of platinum-resistant or refractory ovarian cancer will be excluded. The limitation is that the results of network meta-analyses do not yet have the same level of evidence as direct head-to-head trials. However, it is a useful complementary method when direct comparative studies can not be performed. We plan to publish the results of this systematic review and network meta-analysis in peer-reviewed scientific journals, conferences, and the mass media. Trial registration: This protocol has been registered on the PROSPERO international prospective Register of Systematic Reviews (PROSPERO CRD42024511248). 

    Keywords: PARP inhibitor, ovarian cancer, randomized controlled trials, Phase III, protocol, network meta-analysis abstract

    Received: 05 Dec 2024; Accepted: 06 Jan 2025.

    Copyright: © 2025 Peng and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xiaolian Peng, Xiegang Branch, Dongguan Municipal People's Hospital, Guang Dong Province, China, Dongguan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.